

B4
CONCL'D

2. (Amended) [An] The antibody [as in] of Claim [1,] 21 wherein said murine monoclonal antibody is a neutralizing antibody against [RSV] respiratory syncytial virus.

3. (Amended) [An] The antibody [as in] of Claim [1,] 21 wherein said murine monoclonal antibody is an antibody against [RSV] respiratory syncytial virus F protein.

4. (Amended) [An] The antibody [as in] of Claim 3[,] wherein said murine monoclonal antibody is a neutralizing antibody against [RSV] respiratory syncytial virus F protein.

B5

6. (Amended) [An] The antibody of Claim [5] 3 wherein said murine antibody against [RSV] respiratory syncytial virus F protein is specific for antigenic site A of said protein. .

7. (Amended) [A human] The antibody of Claim [5] 3 wherein said murine antibody against [RSV] respiratory syncytial virus F protein is specific for antigenic site C of said protein.

✓
ADD THE FOLLOWING CLAIMS:

B6
CONT'D.

21. An antibody against respiratory syncytial virus, comprising:
a human constant region, a heavy chain and light chain variable region, each of which comprises a framework region, at least a portion of which is human, and three complementarity determining regions, each complementarity determining region being derived from a murine monoclonal antibody.

22. A process for preventing or treating a respiratory syncytial virus infection in an animal, comprising: